ADC

Overview of ADC Drugs
December 20, 2024

Overview of ADC Drugs

One of the hottest new cancer treatments are Antibody-Drug Conjugates (ADCs). 15 ADCs are approved so far and over 210 are in clinical trials. The ADC drug development has entered a phase of proliferation over the past couple of years on several target (HER2, EGFR, Trop2, CLDN18.2, Nectin-4), with high efficacy and safety. Drug combination therapy and […]

Read Full Article
Current Four-generation ADCs and Next-generation ADCs
October 21, 2024

Current Four-generation ADCs and Next-generation ADCs

Since the first ADC drug Mylotarg (gemtuzumab ozogamicin) was approved by the FDA in 2000, a total of 15 ADC drugs have been approved for marketing worldwide to treat hematological malignancies and solid tumors. In addition, more than 400 ADC drugs are in different stages of development. Of the 15 approved ADC drugs, 13 are […]

Read Full Article
Categories
Recent Posts
A Cholesterol Drug Reopens a Door for a Rare Glycosylation DisorderA Cholesterol Drug Reopens a Door for a Rare Glycosylation Disorder
Enzymatic Glycosylation and Amidation Deliver Safer and More Potent Polyene AntifungalsEnzymatic Glycosylation and Amidation Deliver Safer and More Potent Polyene Antifungals
Highly Fucosylated, Poorly Sialylated: The Fc Glycan Signature of Anti-PGL-I IgG1 in LeprosyHighly Fucosylated, Poorly Sialylated: The Fc Glycan Signature of Anti-PGL-I IgG1 in Leprosy
PocketXMol: A Unified Atom-Level AI for Molecular Docking and DesignPocketXMol: A Unified Atom-Level AI for Molecular Docking and Design